Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 17/20 | 0.40 |
| ▸ | DDB1 | Q16531 | 12/20 | 0.40 |
| ▸ | MPI | P34949 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.37 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.37 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | MAOA | P21397 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21687114 | 0.83 | MPI (0.49) | CRBNDDB1MPIALDH1A1CHRM2 | |
| SCHEMBL21687135 | 0.82 | CRBN (0.37) | CRBNDDB1ALDH1A1CHRM2OPRM1 | |
| SCHEMBL21687112 | 0.79 | CRBN (0.46) | CRBNDDB1ALDH1A1CHRM2OPRM1 | |
| SCHEMBL21687116 | 0.77 | CRBN (0.52) | CRBNDDB1MPIALDH1A1CHRM2 | |
| SCHEMBL21687118 | 0.77 | CRBN (0.52) | CRBNDDB1MPIALDH1A1CHRM2 | |
| SCHEMBL21687119 | 0.77 | CRBN (0.48) | CRBNDDB1ALDH1A1CHRM2OPRM1 | |
| SCHEMBL21687108 | 0.76 | CRBN (0.56) | CRBNDDB1ALDH1A1CHRM2OPRM1 | |
| SCHEMBL14142449 | 0.71 | CRBN (0.65) | CRBNDDB1ALDH1A1CHRM2OPRM1 | |
| SCHEMBL21687125 | 0.71 | MPI (0.48) | CRBNDDB1MPIALDH1A1TSHR | |
| SCHEMBL21687127 | 0.71 | MPI (0.60) | CRBNDDB1MPITSHRMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210292315-A1 | SELENIUM-CONTAINING ISOXAZOLAMINE COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF | SHANGHAI XINGYE PHARMACEUTICAL TECHNOLOGY CO., LTD (CN) | 2021-09-23 | — | — | US | disclosed |
| WO-2020020099-A1 | SELENIUM-CONTAINING ISOXAZOLAMINE COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF | 上海星叶医药科技有限公司 | 2020-01-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210292315-A1 | SELENIUM-CONTAINING ISOXAZOLAMINE COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF | AIFM2, GPX1, AIFM1 | CRBN 3372/4885DDB1 4153/4885MPI 3496/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.